These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29522253)

  • 41. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women.
    Falcão A; Vaz-da-Silva M; Gama H; Nunes T; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2013 Aug; 105(3):368-76. PubMed ID: 23570863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The possible role of enterohepatic cycling on bioavailability of norethisterone and gestodene in women using combined oral contraceptives.
    Elomaa K; Ranta S; Tuominen J; Lähteenmäki P
    Contraception; 2001 Jan; 63(1):13-8. PubMed ID: 11257243
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones.
    Adlercreutz H; Pulkkinen MO; Hämäläinen EK; Korpela JT
    J Steroid Biochem; 1984 Jan; 20(1):217-29. PubMed ID: 6231418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of norethisterone and levonorgestrel in low-dose multiphasic oral contraceptives on serum lipids.
    Wiik P; Nordby J; Paulsen JE
    Acta Obstet Gynecol Scand; 1993 Oct; 72(7):550-5. PubMed ID: 8213103
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.
    Inglis AM; Miller AK; Culkin KT; Finnerty D; Patterson SD; Jorkasky DK; Freed MI
    J Clin Pharmacol; 2001 Jun; 41(6):683-90. PubMed ID: 11402638
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
    Sivasubramanian R; Chakraborty A; Rouzade-Dominguez ML; Neelakantham S; Jakab A; Mensinga T; Legangneux E; Woessner R; Ufer M
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):550-6. PubMed ID: 25943176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estimating systemic exposure to ethinyl estradiol from an oral contraceptive.
    Westhoff CL; Pike MC; Tang R; DiNapoli MN; Sull M; Cremers S
    Am J Obstet Gynecol; 2015 May; 212(5):614.e1-7. PubMed ID: 25511238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-acting hormonal contraceptives for women.
    Garza-Flores J; Hall PE; Perez-Palacios G
    J Steroid Biochem Mol Biol; 1991; 40(4-6):697-704. PubMed ID: 1958567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Nash HA
    Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of losigamone on the pharmacokinetics of a combined oral contraceptive in healthy female volunteers.
    Dienel A; Klement S; Müller F
    Arzneimittelforschung; 2004; 54(3):152-9. PubMed ID: 15112861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of a low-dose monthly injectable contraceptive system: I. Choice of compounds, dose and administration route.
    Garza-Flores J; Diaz-Sanchez V; Jimenez-Thomas S; Rudel HW
    Contraception; 1984 Oct; 30(4):371-9. PubMed ID: 6509988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics.
    Scheffler MR; Colburn W; Kook KA; Thomas SD
    Clin Pharmacol Ther; 1999 May; 65(5):483-90. PubMed ID: 10340913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
    Vonk MC; Guillén-Del-Castillo A; Kreuter M; Avis M; Marzin K; Mack SR; Wind S; Gahlemann M
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):81-89. PubMed ID: 34664183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical and biological justifications for the use of Triella].
    McGuire JL; Pasquale SA; Castaigne JP
    Rev Fr Gynecol Obstet; 1986 Dec; 81(12):731-6. PubMed ID: 3823727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative performance of a combined injectable contraceptive (50 mg norethisterone enanthate plus 5mg estradiol valerate) and a combined oral contraceptive (0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol) in adolescents.
    Molina RC; Sandoval JZ; Montero AV; Oyarzún PG; Molina TG; González EA
    J Pediatr Adolesc Gynecol; 2009 Feb; 22(1):25-31. PubMed ID: 19232299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.
    LeBel M; Masson E; Guilbert E; Colborn D; Paquet F; Allard S; Vallée F; Narang PK
    J Clin Pharmacol; 1998 Nov; 38(11):1042-50. PubMed ID: 9824786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of avosentan (SPP3OI) on the pharmacokinetics of a second generation oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
    Dieterle W; Mann J
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):668-74. PubMed ID: 17190377
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thromboembolic safety of norethisterone vs levonorgestrel in combined oral contraceptive users: a pooled analysis of 4 large prospective cohort studies.
    Barnett C; Bauerfeind A; Von Stockum S; Heinemann K
    AJOG Glob Rep; 2022 Feb; 2(1):100041. PubMed ID: 36274960
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
    Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
    Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Preclinical research and development of norethisterone].
    Mcguire JL; Hahn DW; Philipps A
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):437-44. PubMed ID: 12280212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.